A cohort description and comparison of four European national diabetes registries for the REDDIE project

IF 3.4 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Diabetic Medicine Pub Date : 2025-10-01 DOI:10.1111/dme.70112

Jonah J. C. Thomas, Stefanie Lanzinger, Kathrine Kold Soerensen, Henrik Imberg, Stefanie Schmid, Emma Barron, Reinhard Holl, Ulrik Pedersen-Bjergaard, Amanda Adler, Martina Vettoretti, Shivani Misra, Jonathan Valabhji, Kamlesh Khunti, Marcus Lind, Christian Torp-Pedersen, Julia K. Mader, Pratik Choudhary, the REDDIE study group

{"title":"A cohort description and comparison of four European national diabetes registries for the REDDIE project","authors":"Jonah J. C. Thomas, Stefanie Lanzinger, Kathrine Kold Soerensen, Henrik Imberg, Stefanie Schmid, Emma Barron, Reinhard Holl, Ulrik Pedersen-Bjergaard, Amanda Adler, Martina Vettoretti, Shivani Misra, Jonathan Valabhji, Kamlesh Khunti, Marcus Lind, Christian Torp-Pedersen, Julia K. Mader, Pratik Choudhary, the REDDIE study group","doi":"10.1111/dme.70112","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>The Real-world Evidence for Decisions in Diabetes (REDDIE) project aims to better understand how to use real-world data (RWD) to advance research related to diabetes. To achieve this aim, four national registries (National Diabetes Audit (NDA (England)), Diabetes Patienten Verlaufsdokumentation (DPV (Germany)), Swedish National Registries (NDR), Danish National Registries (DNR)) are contributing data to the REDDIE project. This publication aims to describe the four registries and compare their unique strengths and limitations.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Data regarding the four registries were extracted from their inception until 2024. Data regarding demographics, prescriptions, outcomes, lifestyle and diabetes-specific variables (usage of continuous glucose monitors) were summarised.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A core set of variables was identified across all four registries in the REDDIE project. Demographic information, diabetes-related medication, measures of glycaemic control and lifestyle factors are measured in all four registries. The DNR, NDA and NDR also contain wider prescription data, diagnosis data (cardiovascular disease, retinopathy) and mortality data. The DPV registry does not contain these data but contains detailed data on continuous glucose monitor and insulin pump usage. Differences in the methodologies employed and data fields collected were identified, including in data collection techniques, linkage processes, follow-up protocols and the range of variables recorded. Even with this diversity in data collection, there remains a significant opportunity to perform collaborative analysis between the registries. By combining RWD collected in different populations and health care systems with diverse demographics, the transferability of evidence will increase, enabling research studies to be more representative and inclusive of diverse populations.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The four registries that make up the REDDIE project contain many commonly collected variables. However, each registry presents specific strengths and limitations. By including all four databases, the REDDIE project benefits from the complementary strengths of each database.</p>\n </section>\n </div>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":"42 11","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.70112","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetic Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dme.70112","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

The Real-world Evidence for Decisions in Diabetes (REDDIE) project aims to better understand how to use real-world data (RWD) to advance research related to diabetes. To achieve this aim, four national registries (National Diabetes Audit (NDA (England)), Diabetes Patienten Verlaufsdokumentation (DPV (Germany)), Swedish National Registries (NDR), Danish National Registries (DNR)) are contributing data to the REDDIE project. This publication aims to describe the four registries and compare their unique strengths and limitations.

Methods

Data regarding the four registries were extracted from their inception until 2024. Data regarding demographics, prescriptions, outcomes, lifestyle and diabetes-specific variables (usage of continuous glucose monitors) were summarised.

Results

A core set of variables was identified across all four registries in the REDDIE project. Demographic information, diabetes-related medication, measures of glycaemic control and lifestyle factors are measured in all four registries. The DNR, NDA and NDR also contain wider prescription data, diagnosis data (cardiovascular disease, retinopathy) and mortality data. The DPV registry does not contain these data but contains detailed data on continuous glucose monitor and insulin pump usage. Differences in the methodologies employed and data fields collected were identified, including in data collection techniques, linkage processes, follow-up protocols and the range of variables recorded. Even with this diversity in data collection, there remains a significant opportunity to perform collaborative analysis between the registries. By combining RWD collected in different populations and health care systems with diverse demographics, the transferability of evidence will increase, enabling research studies to be more representative and inclusive of diverse populations.

Conclusion

The four registries that make up the REDDIE project contain many commonly collected variables. However, each registry presents specific strengths and limitations. By including all four databases, the REDDIE project benefits from the complementary strengths of each database.

Abstract Image

查看原文本刊更多论文

REDDIE项目中四个欧洲国家糖尿病登记的队列描述和比较。

目的：糖尿病决策的真实世界证据（REDDIE）项目旨在更好地了解如何使用真实世界数据（RWD）来推进与糖尿病相关的研究。为了实现这一目标，四个国家登记处（国家糖尿病审计（NDA（英格兰）），糖尿病患者verlaufsdocumentation （DPV（德国）），瑞典国家登记处（NDR），丹麦国家登记处（DNR））为REDDIE项目提供数据。本出版物旨在描述这四个注册中心，并比较它们的独特优势和局限性。方法：从四个注册中心建立到2024年的数据进行提取。总结了有关人口统计学、处方、结局、生活方式和糖尿病特异性变量（连续血糖监测仪的使用）的数据。结果：在REDDIE项目的所有四个注册中心中确定了一组核心变量。人口统计信息、糖尿病相关药物、血糖控制措施和生活方式因素在所有四个登记处都进行了测量。DNR、NDA和NDR还包含更广泛的处方数据、诊断数据（心血管疾病、视网膜病变）和死亡率数据。DPV注册表不包含这些数据，但包含连续血糖监测和胰岛素泵使用的详细数据。确定了所采用的方法和收集的数据领域的差异，包括数据收集技术、联系过程、后续协议和记录的变量范围。即使在数据收集方面存在这种多样性，仍然有很大的机会在注册中心之间执行协作分析。通过将在不同人群和卫生保健系统中收集的RWD与不同人口统计数据相结合，将增加证据的可转移性，使研究更具代表性和包容性。结论：组成REDDIE项目的四个注册表包含许多通常收集的变量。然而，每个注册中心都有其特定的优点和局限性。通过包括所有四个数据库，REDDIE项目可以从每个数据库的互补优势中获益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetic Medicine 医学-内分泌学与代谢

CiteScore

7.20

自引率

5.70%

发文量

229

审稿时长

3-6 weeks

期刊介绍： Diabetic Medicine, the official journal of Diabetes UK, is published monthly simultaneously, in print and online editions. The journal publishes a range of key information on all clinical aspects of diabetes mellitus, ranging from human genetic studies through clinical physiology and trials to diabetes epidemiology. We do not publish original animal or cell culture studies unless they are part of a study of clinical diabetes involving humans. Categories of publication include research articles, reviews, editorials, commentaries, and correspondence. All material is peer-reviewed. We aim to disseminate knowledge about diabetes research with the goal of improving the management of people with diabetes. The journal therefore seeks to provide a forum for the exchange of ideas between clinicians and researchers worldwide. Topics covered are of importance to all healthcare professionals working with people with diabetes, whether in primary care or specialist services. Surplus generated from the sale of Diabetic Medicine is used by Diabetes UK to know diabetes better and fight diabetes more effectively on behalf of all people affected by and at risk of diabetes as well as their families and carers.”